Alpha Cognition opened at $8.62, in line with its previous close of $8.62. In the last trading session, the stock traded between $8.44 and $9.04. It showed a sideways intraday trend.
An investment of $100 made 2 years ago in Alpha Cognition is now worth
$ 150.40
Giving a profit of
$ 50.40 (50.40%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.05 (-0.55%)
Day High
$9.04
Day Low
$8.44
Day Open
$8.62
Prev Close
$8.62
Volume
1,32,370
1W Return
-1.46%
1M Return
-3.24%
3M Return
-5.22%
6M Return
44.08%
1Y Return
40.08%
Market Cap ($ Mn)
187
PE Ratio
-
PB Ratio
3.75
PEG Ratio
-
ROE
-49.63%
ROCE
-46.00%
EPS (TTM)
$-0.40
1 Week
-1.46%
1 Month
-3.24%
3 Months
-5.22%
6 Months
44.08%
9 Months
64.55%
Alpha Cognition Q3FY26 Revenue Up 230% YoY to $7.8 million
Net product revenue rose 230% YoY to $7.777 million in Q3FY26. Loss per share improved to $(0.35) from $(0.38) in Q2FY26. Cumulative prescribers reached 2,438, exceeding full-year goals early. Operating loss narrowed to $6.4 million as expenses stayed flat.
YesterdayAlpha Cognition executives to participate in upcoming investor events
Alpha Cognition Inc. CEO Michael McFadden and COO Lauren D’Angelo will participate in investor events in late 2026. The company will hold 1x1 meetings at the Craig-Hallum Alpha Select Conference on November 17, 2026. A fireside chat is scheduled for the Stonegate CEO Series on December 10, 2026, at 12 pm EST. Alpha Cognition focuses on therapeutics for neurodegenerative disorders like Alzheimer’s disease and mTBI.
6 days agoAlpha Cognition announces initial CONVERGE real-world data on ZUNVEYL
Alpha Cognition Inc. released initial results from the CONVERGE real-world evidence program. The study analyzes 180-day titration and concomitant medication patterns in long-term care. Data covers residents receiving ZUNVEYL, donepezil, galantamine, or rivastigmine. The analysis includes both AChEI-naive patients and those switching from other therapies.
1mo agoAlpha Cognition Q2 sales beat estimates, EPS misses consensus
Alpha Cognition reported Q2 2026 sales of $6.092 million, beating estimates by 38.95% and surging 267.65% YoY. However, EPS of $(0.40) missed the consensus of $(0.39). The company lowered FY26 operating expense guidance to $50-54 million. Cash stood at $41.4 million.
3mo agoAlpha Cognition CEO to join B. Riley Securities panel on July 16
Alpha Cognition Inc. CEO Michael McFadden will participate in a panel discussion at the B. Riley Securities Mind, Muscle & Vision Summit on July 16 in Boston. The panel focuses on late-stage and commercial CNS small cap companies. No live webcast will be available for the session.
4mo agoRaymond James initiates Alpha Cognition coverage with Outperform rating
Raymond James analyst Ryan Deschner initiated coverage on Alpha Cognition, assigning an Outperform rating and setting a price target of $20.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 2 years ago in Alpha Cognition is now worth
$ 150.40
Giving a profit of
$ 50.40 (50.40%)
Note: Past profits do not guarantee future returns.
